Literature DB >> 11020801

Potent inhibition of human immunodeficiency virus type 1 replication by conditionally replicating human immunodeficiency virus-based lentiviral vectors expressing envelope antisense mRNA.

M R Mautino1, R A Morgan.   

Abstract

We describe an HIV-based lentiviral vector that expresses a 1-kb antisense mRNA directed against the HIV-1 mRNAs containing env sequences. The expression of antisense env mRNAs (envAS) does not inhibit the synthesis of p24 expressed from the HIV-1 helper plasmid used to package the vector, as this helper has a deletion in the env gene. This allows the production of high-titer VSV-G pseudotyped lentiviral particles. In challenge experiments using unselected populations of SupT1 cells transduced with this vector, a complete inhibition of HIV-1 replication was observed for long periods of in vitro culture, even at high HIV-1 infectious doses. The potent inhibition of HIV-1 replication by this vector correlated with a low occurrence of mobilization of the vector to previously untransduced cells. The infectivity of the wild-type HIV-1 that escapes inhibition was highly inhibited, suggesting that the vector is providing HIV-1 inhibition of replication not only due to its antisense effect but also by competing for encapsidation and mobilization to noninfected cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11020801     DOI: 10.1089/10430340050143444

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  9 in total

1.  Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by HIV-1-based lentivirus vectors expressing transdominant Rev.

Authors:  M R Mautino; N Keiser; R A Morgan
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells.

Authors:  Ronald T Mitsuyasu; Thomas C Merigan; Andrew Carr; Jerome A Zack; Mark A Winters; Cassy Workman; Mark Bloch; Jacob Lalezari; Stephen Becker; Lorna Thornton; Bisher Akil; Homayoon Khanlou; Robert Finlayson; Robert McFarlane; Don E Smith; Roger Garsia; David Ma; Matthew Law; John M Murray; Christof von Kalle; Julie A Ely; Sharon M Patino; Alison E Knop; Philip Wong; Alison V Todd; Margaret Haughton; Caroline Fuery; Janet L Macpherson; Geoff P Symonds; Louise A Evans; Susan M Pond; David A Cooper
Journal:  Nat Med       Date:  2009-02-15       Impact factor: 53.440

Review 3.  RNA-based gene therapy for the treatment and prevention of HIV: from bench to bedside.

Authors:  Skye J Zeller; Priti Kumar
Journal:  Yale J Biol Med       Date:  2011-09

4.  Phase I/II Clinical Trials Using Gene-Modified Adult Hematopoietic Stem Cells for HIV: Lessons Learnt.

Authors:  Ronald T Mitsuyasu; Jerome A Zack; Janet L Macpherson; Geoff P Symonds
Journal:  Stem Cells Int       Date:  2011-06-13       Impact factor: 5.443

Review 5.  Foamy virus vectors for HIV gene therapy.

Authors:  Miles E Olszko; Grant D Trobridge
Journal:  Viruses       Date:  2013-10-22       Impact factor: 5.048

Review 6.  Prospects for Foamy Viral Vector Anti-HIV Gene Therapy.

Authors:  Arun K Nalla; Grant D Trobridge
Journal:  Biomedicines       Date:  2016-03-29

7.  Insulators to Improve the Safety of Retroviral Vectors for HIV Gene Therapy.

Authors:  Diana L Browning; Grant D Trobridge
Journal:  Biomedicines       Date:  2016-02-02

8.  Protection of stem cell-derived lymphocytes in a primate AIDS gene therapy model after in vivo selection.

Authors:  Grant D Trobridge; Robert A Wu; Brian C Beard; Sum Ying Chiu; Nina M Muñoz; Dorothee von Laer; John J Rossi; Hans-Peter Kiem
Journal:  PLoS One       Date:  2009-11-02       Impact factor: 3.240

9.  Foamy combinatorial anti-HIV vectors with MGMTP140K potently inhibit HIV-1 and SHIV replication and mediate selection in vivo.

Authors:  H-P Kiem; R A Wu; G Sun; D von Laer; J J Rossi; G D Trobridge
Journal:  Gene Ther       Date:  2009-09-10       Impact factor: 5.250

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.